Medolife's Therapeutic Scorpion Peptide Proves Successful in Treating COVID-19 Patients in Dominican Republic Study
BURBANK, CA / ACCESSWIRE / January 27, 2021 / Medolife Rx, Inc., ("Medolife") a majority owned subsidiary of Quanta, Inc. (OTC PINK:QNTA) today announced In a recent study, a total of 400 patients in the Dominican Republic - where, a majority tested positive for COVID-19, and a small portion were COVID-19 symptomatic even though they tested negative for COVID-19 - reported a 100 percent improvement in symptoms after being administered Escozine®. Many of the patients participating in the study reported severe COVID-19 symptoms, such as difficulty breathing, pain and high fever, which Escozine® was able to relieve within 5 days of treatment. Even patients under ventilators were discharged within days, thanks to this novel product. Located in Santo Domingo, Dominican Republic, The Cruz Jiminian Clinic has carried out this ongoing study since August 2020, and has reported 0 COVID-19 related deaths after the clinic began administering Escozine®. Escozine®, produced by Medolife Rx, Inc., ("Medolife"), is a therapeutic consisting of small molecule peptides derived from a specific species of scorpions, Rhopalurus princeps, endemic to the Dominican Republic. After the successful study, Escozine® is on fast-track to be registered with the Ministry of Health in the Dominican Republic in Q1 2021. Medolife also submitted the study data to the US FDA, which is currently under review for permission to repeat the clinical trial in the United States. In addition to supporting the recovery of COVID-19 patients, Escozine® was registered and certified for cancer treatment by the Ministry of Health in the Dominican Republic in 2010.
Scorpion Venom Most Expensive Liquid in the World
From treating cancer to pain management to fighting viral infections, this unique peptide has a vast range of therapeutic applications. In the last decade, a growing interest from Big Pharma companies has caused an increase in the liquid's value: costing $39 million per gallon.
Medolife's Dominican Republic Scorpion Reservation is one of the largest breeding grounds for scorpions on earth. Combined with the company's more than 15 years of research, Medolife is positioned to continue developing groundbreaking formulas and pharmaceutical-grade medications for consumer use.
Pharma's Growing Interest in Scorpion Peptide-Based Therapeutics
Venom has been studied for therapeutic uses for decades. In 2015, the European FP7 Venomics Project studied over 200 animal species worldwide for venom-to-drug development.
Currently, six peptide drugs on the market are derived from venoms, and the pharmaceutical industry has demonstrated a growing interest in these naturally derived therapeutics. The first venom-derived drug, Captopril, was developed by Bristol-Myers Squibb. The drug, derived from snake venom, was approved for use in the 1980s to treat high blood pressure.
Snail venom was used in the development of Prialt®, which is used to treat pain. Also, Byetta®, used to treat type 2 diabetes, was derived from a lizard.
How Venom-Based Drugs Work
The Rhopalurus princeps venom contains a small molecular peptide that can pass through the blood-brain barrier in the body. Four small molecular peptides in the venom can attack various diseases in humans. To do this, it blocks small-conductance chloride, sodium, potassium and calcium ion channels, and it also binds preferentially to abnormal and cancerous cells, leaving the normal cells intact. Medolife holds exclusive rights to the Rhopalurus princeps scorpion per the agreement signed with the Ministry of Environment and Natural Resources of the Dominican Republic.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.